Arrowhead Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ARWR Nasdaq 2834 https://arrowheadpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arrowhead Pharmaceuticals Inc

Arrowhead Receives FDA Fast Track Designation for ARO-APOC3 - Mar 20th, 2023 11:30 am
Investing in Arrowhead Pharmaceuticals (NASDAQ:ARWR) five years ago would have delivered you a 329% gain - Mar 6th, 2023 10:28 am
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference - Mar 3rd, 2023 12:30 pm
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases - Feb 28th, 2023 12:30 pm
12 High Growth Healthcare Stocks to Buy - Feb 26th, 2023 1:04 pm
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals - Feb 15th, 2023 4:29 pm
Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results - Feb 15th, 2023 12:30 pm
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2023 Earnings Call Transcript - Feb 8th, 2023 7:13 pm
ARWR: Catalyst-Rich 2023… - Feb 8th, 2023 10:34 am
Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results - Feb 6th, 2023 9:00 pm
I Found a Good-Looking Arrowhead in This Biotech ETF - Feb 3rd, 2023 5:50 pm
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis - Feb 2nd, 2023 12:30 pm
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results - Jan 25th, 2023 12:30 pm
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Jan 24th, 2023 1:22 pm
ARWR: Encouraging Results for Phase 2 SEQUOIA Trial… - Jan 10th, 2023 3:15 pm
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study - Jan 9th, 2023 3:12 pm
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference - Dec 21st, 2022 9:00 pm
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study - Dec 21st, 2022 12:30 pm
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen - Dec 20th, 2022 12:30 pm
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Dec 15th, 2022 9:30 pm